Onkos Surgical

Executive Summary

Onkos Surgical is a privately held medical device company focused on precision orthopaedic solutions for musculoskeletal oncology and complex reconstructive surgery. Founded in 2015 and headquartered in Parsippany, New Jersey, the company has developed a differentiated portfolio anchored by the NanoCept® Antibacterial Implant Technology, the first FDA-granted antibacterial coating for orthopedic implants. This technology addresses a critical unmet need in oncology patients, who are at heightened risk of infection due to immunosuppression. Onkos' product offerings include the ELEOS™ Limb Salvage System for tumor resection and reconstruction, the JTS expandable prosthesis for pediatric patients, and the My3D® personalized solutions platform for custom implants. By combining antimicrobial protection with advanced surgical implants, Onkos aims to reduce complications and improve outcomes in a high-risk, underserved patient population. The company operates in a niche but growing market, driven by rising incidence of bone cancers and soft-tissue sarcomas, as well as increasing adoption of limb-sparing surgeries. As a private entity, Onkos has not disclosed funding details, but its proprietary technology and regulatory milestones suggest a favorable trajectory. Key challenges include limited commercial scale and competition from larger orthopaedic firms. However, the company's focus on a specialized clinical need and its FDA-cleared platform position it for potential growth. Over the near term, Onkos is expected to expand clinical evidence, pursue additional indications, and explore strategic partnerships to broaden market access.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded indication of NanoCept coating in revision surgery75% success
• Q2 2026Publication of pivotal clinical study results for ELEOS Limb Salvage System80% success
• Q4 2026Strategic partnership or distribution agreement for My3D personalized solutions60% success